You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,923,564


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,923,564
Title:Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Abstract: Disclosed herein are methods for synthesizing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide. Also disclosed herein is the hemi-tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and methods for obtaining the salt. Further disclosed are various crystalline forms of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)-p- henylmethyl)carbamide and its hemi-tartrate salt including various polymorphs and solvates.
Inventor(s): Thygesen; Mikkel Boas (Copenhagen East, DK), Schlienger; Nathalie (Frederiksberg, DK), Tolf; Bo-Ragnar (Malmo, SE), Andersson; Carl-Magnus A. (Hjarup, SE), Blatter; Fritz (Reinach, CH), Berghausen; Jorg (Lorrach, DE)
Assignee: ACADIA Pharmaceuticals, Inc. (San Diego, CA)
Application Number:12/795,547
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,923,564
Patent Claims: 1. Crystalline form C of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide tartrate of formula IV, ##STR00032## which shows an endothermic signal at 177.degree. C. as measured by differential scanning calorimetry.

2. The crystalline form of claim 1, wherein the endothermic signal at 177.degree. C. has an enthalpy of fusion of about 129 J/g.

3. The crystalline form of claim 1, wherein the endothermic signal at 177.degree. C. is a melting temperature.

4. The crystalline form of claim 1, which results in a weight loss of about 0.9% below 150.degree. C. as measured by thermogravimetric analysis.

5. The crystalline form of claim 1 that has less than 1000 ppm of residual solvent.

6. The crystalline form of claim 1 that has less than 200 ppm of residual solvent.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.